Your browser is no longer supported. Please, upgrade your browser.
Settings
RGEN [NASD]
Repligen Corporation
Index- P/E192.51 EPS (ttm)1.11 Insider Own0.60% Shs Outstand53.19M Perf Week3.49%
Market Cap11.70B Forward P/E95.95 EPS next Y2.22 Insider Trans-19.11% Shs Float50.34M Perf Month8.36%
Income59.90M PEG6.11 EPS next Q0.42 Inst Own84.50% Short Float3.08% Perf Quarter0.49%
Sales366.30M P/S31.93 EPS this Y155.50% Inst Trans2.21% Short Ratio3.87 Perf Half Y25.59%
Book/sh28.75 P/B7.42 EPS next Y16.45% ROA3.80% Target Price236.71 Perf Year102.86%
Cash/sh13.08 P/C16.31 EPS next 5Y31.50% ROE5.00% 52W Range102.13 - 228.84 Perf YTD11.31%
Dividend- P/FCF291.71 EPS past 5Y31.90% ROI4.00% 52W High-8.06% Beta0.83
Dividend %- Quick Ratio2.50 Sales past 5Y34.40% Gross Margin57.20% 52W Low106.01% ATR7.14
Employees1128 Current Ratio2.80 Sales Q/Q56.30% Oper. Margin19.10% RSI (14)56.27 Volatility2.66% 3.53%
OptionableYes Debt/Eq0.16 EPS Q/Q420.70% Profit Margin16.40% Rel Volume0.35 Prev Close213.30
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 BMO Payout0.00% Avg Volume400.49K Price210.40
Recom1.70 SMA205.12% SMA502.96% SMA20018.32% Volume106,115 Change-1.36%
Nov-10-20Initiated KeyBanc Capital Markets Overweight $241
Aug-24-20Reiterated H.C. Wainwright Buy $151 → $168
Jun-30-20Reiterated H.C. Wainwright Buy $143 → $151
May-07-20Reiterated H.C. Wainwright Buy $100 → $143
Mar-23-20Reiterated H.C. Wainwright Buy $110 → $100
Nov-15-19Initiated Stifel Buy
Nov-01-19Upgrade First Analysis Sec Outperform → Strong Buy $107 → $110
Oct-15-19Initiated SVB Leerink Outperform $100
Aug-28-19Reiterated First Analysis Sec Outperform $95 → $107
Aug-23-19Resumed Stephens Overweight
Jul-22-19Upgrade H.C. Wainwright Neutral → Buy $110
Dec-17-18Upgrade CL King Neutral → Buy
Nov-12-18Downgrade CL King Buy → Neutral
Sep-26-18Initiated H.C. Wainwright Neutral $49
Dec-08-17Initiated Citigroup Buy $45
Dec-05-17Initiated JP Morgan Overweight $42
Nov-13-17Initiated CL King Buy
Oct-02-17Upgrade First Analysis Sec Equal-Weight → Overweight $47
Jul-21-17Initiated William Blair Outperform
Feb-13-17Upgrade Piper Jaffray Neutral → Overweight
Apr-13-21 05:27PM  
05:24PM  
Apr-12-21 10:53AM  
08:26AM  
Apr-09-21 10:57AM  
09:40AM  
Apr-07-21 05:14PM  
Apr-06-21 12:33PM  
09:05AM  
Apr-05-21 01:16PM  
Apr-01-21 08:17AM  
06:33AM  
Mar-30-21 11:43AM  
10:06AM  
Mar-28-21 06:11AM  
Mar-26-21 11:30AM  
Mar-25-21 08:56AM  
Mar-19-21 09:17AM  
Mar-17-21 07:30AM  
Mar-09-21 09:31AM  
09:11AM  
Mar-08-21 10:56AM  
Mar-03-21 12:40PM  
07:30AM  
Mar-02-21 10:02AM  
Mar-01-21 10:33AM  
Feb-25-21 11:56PM  
Feb-24-21 04:41PM  
03:30PM  
07:47AM  
07:30AM  
06:30AM  
Feb-22-21 07:30AM  
04:27AM  
Feb-12-21 11:16AM  
Feb-11-21 05:50PM  
03:00PM  
11:05AM  
Feb-08-21 07:36AM  
Feb-05-21 05:50PM  
Feb-03-21 12:47PM  
Jan-26-21 01:42PM  
Jan-19-21 01:13PM  
Jan-15-21 05:23PM  
11:12AM  
Jan-14-21 03:16PM  
01:12PM  
Jan-09-21 08:00AM  
Jan-08-21 01:50PM  
Jan-05-21 05:14PM  
Jan-04-21 01:00PM  
Jan-01-21 10:01AM  
Dec-30-20 10:24AM  
Dec-28-20 08:33AM  
Dec-24-20 03:47AM  
Dec-21-20 10:16AM  
08:48AM  
08:46AM  
08:24AM  
Dec-20-20 03:14PM  
Dec-18-20 11:04AM  
08:36AM  
08:34AM  
Dec-17-20 11:58AM  
08:47AM  
Dec-16-20 05:17AM  
Dec-15-20 11:30AM  
Dec-14-20 01:05PM  
Dec-11-20 01:03PM  
Dec-10-20 04:18PM  
10:52AM  
Dec-08-20 12:20PM  
10:15AM  
Dec-07-20 09:41PM  
07:22AM  
Dec-05-20 11:32AM  
Dec-04-20 08:29AM  
Nov-25-20 09:27AM  
Nov-19-20 11:30AM  
08:00AM  
Nov-16-20 09:51AM  
Nov-13-20 09:46AM  
08:31AM  
08:15AM  
Nov-12-20 08:03AM  
Nov-10-20 09:40AM  
Nov-09-20 03:52PM  
01:27PM  
07:56AM  
Nov-06-20 09:17AM  
Nov-05-20 09:45AM  
07:30AM  
Nov-04-20 03:25PM  
Oct-29-20 12:34PM  
Oct-27-20 04:15PM  
Oct-22-20 12:33PM  
07:30AM  
Oct-12-20 02:51PM  
Oct-05-20 12:17PM  
Oct-01-20 06:30AM  
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bylund JamesSVP, Global Operations & ITApr 06Sale204.2536073,5306,324Apr 08 07:55 PM
Gebski ChristineSee RemarksMar 16Sale196.881,400275,63237,140Mar 18 09:47 PM
Hunt AnthonyChief Executive OfficerMar 12Sale190.389,1021,732,847212,762Mar 12 07:34 PM
KURIYEL RALFSenior VP, R&DMar 10Option Exercise34.158,000273,16833,265Mar 12 07:33 PM
KURIYEL RALFSenior VP, R&DMar 10Sale190.448,0001,523,50125,265Mar 12 07:33 PM
Hunt AnthonyChief Executive OfficerMar 04Sale190.1921,9004,165,091221,864Mar 08 09:51 PM
Snodgres JonChief Financial OfficerMar 04Sale192.473,545682,29532,363Mar 08 09:50 PM
KURIYEL RALFSenior VP, R&DMar 04Sale192.002,075398,39625,265Mar 08 09:41 PM
RYAN THOMAS F JRDirectorMar 03Option Exercise26.121,00026,1202,464Mar 04 09:22 PM
RYAN THOMAS F JRDirectorMar 03Sale205.001,000205,0001,464Mar 04 09:22 PM
Snodgres JonChief Financial OfficerJan 25Option Exercise33.874,000135,48033,498Jan 26 09:59 PM
Snodgres JonChief Financial OfficerJan 04Sale191.523,957757,84029,498Jan 06 04:41 PM
KURIYEL RALFSenior VP, R&DDec 16Sale186.1843580,98825,654Dec 18 04:30 PM
Hunt AnthonyChief Executive OfficerNov 19Option Exercise26.0520,000521,000253,327Nov 23 07:03 PM
Hunt AnthonyChief Executive OfficerNov 19Sale185.8020,0003,716,051233,327Nov 23 07:03 PM
RYAN THOMAS F JRDirectorNov 11Option Exercise38.7693436,2022,398Nov 13 04:46 PM
RYAN THOMAS F JRDirectorNov 11Sale187.73934175,3401,464Nov 13 04:46 PM
Snodgres JonChief Financial OfficerNov 10Option Exercise32.403,08699,98636,541Nov 10 09:17 PM
Snodgres JonChief Financial OfficerNov 10Sale193.003,086595,59833,455Nov 10 09:17 PM
Snodgres JonChief Financial OfficerNov 09Option Exercise59.521,893112,67133,455Nov 10 09:17 PM
BARTHELEMY NICOLASDirectorNov 09Sale195.511,214237,3491,450Nov 10 09:18 PM
Snodgres JonChief Financial OfficerNov 09Sale194.69705137,25631,562Nov 10 09:17 PM
Hunt AnthonyChief Executive OfficerSep 10Option Exercise26.0545,3511,181,394278,678Sep 14 07:43 AM
Hunt AnthonyChief Executive OfficerSep 10Sale148.2045,3516,721,018233,327Sep 14 07:43 AM
KURIYEL RALFSenior VP, R&DAug 06Option Exercise33.875,000169,35031,089Aug 10 05:35 PM
KURIYEL RALFSenior VP, R&DAug 06Sale153.795,000768,95026,089Aug 10 05:35 PM
RYAN THOMAS F JRDirectorJul 31Option Exercise67.712,109142,8004,559Aug 04 07:50 PM
RYAN THOMAS F JRDirectorJul 31Sale151.903,095470,1291,464Aug 04 07:50 PM
DAWES KAREN ADirectorJun 18Sale115.2018,7052,154,851100,734Jun 22 04:42 PM
Hunt AnthonyChief Executive OfficerMay 21Option Exercise24.1050,0391,206,140277,194May 26 09:27 PM
Hunt AnthonyChief Executive OfficerMay 21Sale139.7746,9536,562,409230,241May 26 09:27 PM
DAWES KAREN ADirectorMay 20Sale139.4451772,093119,439May 21 09:08 PM
BARTHELEMY NICOLASDirectorMay 18Option Exercise67.712,109142,8005,673May 26 09:24 PM
BARTHELEMY NICOLASDirectorMay 18Sale142.533,009428,8732,664May 26 09:24 PM
DAWES KAREN ADirectorMay 18Sale137.781,600220,448119,956May 19 08:46 PM
KURIYEL RALFSenior VP, R&DMay 15Sale140.6943561,20026,089May 19 08:54 PM
Snodgres JonChief Financial OfficerMay 15Sale140.4366092,68432,267May 19 08:47 PM
KURIYEL RALFSenior VP, R&DMay 13Option Exercise33.268,000266,04034,524May 15 05:37 PM
Snodgres JonChief Financial OfficerMay 13Option Exercise30.7512,194374,95648,321May 15 05:41 PM
KURIYEL RALFSenior VP, R&DMay 13Sale127.808,0001,022,37326,524May 15 05:37 PM
Snodgres JonChief Financial OfficerMay 13Sale128.7415,3941,981,87532,927May 15 05:41 PM
BARTHELEMY NICOLASDirectorApr 22Option Exercise42.071,65269,5005,725Apr 24 05:22 PM
BARTHELEMY NICOLASDirectorApr 22Sale109.992,688295,6533,037Apr 24 05:22 PM
DAWES KAREN ADirectorApr 21Option Exercise3.3011,80038,940120,834Apr 22 06:07 PM
DAWES KAREN ADirectorApr 20Option Exercise3.308,20027,060121,234Apr 22 06:07 PM
DAWES KAREN ADirectorApr 20Sale104.5712,2001,275,717109,034Apr 22 06:07 PM